Search results for "Mira"

showing 10 items of 161 documents

BAL, Mieke. "Tiempos trastornados. Análisis, historias y políticas de la mirada"

2016

ArtículoUNESCO::HISTORIA::Historia por especialidades::Historia del arteBAL Mieke. &quot:HISTORIA::Historia por especialidades::Historia del arte [UNESCO]Tiempos trastornados. Análisis historias y políticas de la mirada&quotBAL Mieke. "Tiempos trastornados. Análisis historias y políticas de la mirada" Artículo
researchProduct

Oxylipin mediated stress response of a miraculin-like protease inhibitor in Hexanoic acid primed eggplant plants infested by Colorado potato beetle

2017

Insect-plant interactions are governed by a complex equilibrium between the mechanisms through which plant recognize insect attack and orchestrate downstream signaling events that trigger plant defense responses, and the mechanisms by which insects overcome plant defenses. Due to this tight and dynamic interplay, insight into the nature of the plant defense response can be gained by analyzing changes in the insect herbivores digestive system upon plant feeding. In this work we have identified a Solanum melongena miraculin-like protease inhibitor in the midgut juice of Colorado potato larvae feeding on eggplant plants treated with the natural inducer of plant defenses hexanoic acid. We analy…

0106 biological sciences0301 basic medicinePhysiologyMiraculinPlant ScienceEggplant01 natural sciences03 medical and health scienceschemistry.chemical_compoundGene Expression Regulation PlantBotanyPlant defense against herbivoryAnimalsColorado potato beetleProtease InhibitorsOxylipinsSolanum melongenaCaproatesMiraculin-like proteinHexanoic acidbiologyColorado potato beetlefungiPlant physiologyfood and beveragesOxylipinbiology.organism_classificationCell biologyColeoptera030104 developmental biologychemistryDefense primingSolanumHexanoic acidAgronomy and Crop ScienceSolanaceae010606 plant biology & botany
researchProduct

β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project

2016

β3-Adrenoceptor agonists were originally considered as a promising drug class for the treatment of obesity and/or type 2 diabetes. When these development efforts failed, they were repositioned for the treatment of the overactive bladder syndrome. Based on the example of the β3-adrenoceptor agonist mirabegron, but also taking into consideration evidence obtained with ritobegron and solabegron, we discuss challenges facing a translational pharmacology program accompanying clinical drug development for a first-in-class molecule. Challenges included generic ones such as ligand selectivity, species differences and drug target gene polymorphisms. Challenges that are more specific included changin…

0301 basic medicineAgonistmedicine.drug_classUrinary BladderAdrenergic beta-3 Receptor AgonistsAdrenergic beta-3 Receptor AgonistsPharmacologyLigandsAntibodiesTranslational Research Biomedical03 medical and health sciencesSolabegronmedicineAnimalsHumansPharmacology (medical)PharmacologyUrinary Bladder Overactivebusiness.industryDrug RepositioningSyndromeOveractive bladder syndromeDrug repositioning030104 developmental biologyDrug classDrug developmentReceptors Adrenergic beta-3Adrenergic beta-3 Receptor AntagonistsbusinessMirabegronmedicine.drugPharmacology & Therapeutics
researchProduct

β(3)‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?

2019

β(3)‐Adrenoceptor agonists are used in the treatment of overactive bladder syndrome. Although the relaxant response to adrenergic stimulation in human detrusor smooth muscle cells is mediated mainly via β(3)‐adrenoceptors, the plasma concentrations of the therapeutic dose of mirabegron, the only clinically approved β(3)‐adrenoceptor agonist, are considerably lower than the EC(50) for causing direct relaxation of human detrusor, suggesting a mechanism of action other than direct relaxation of detrusor smooth muscle. However, the site and mechanism of action of β(3)‐adrenoceptor agonists in the bladder have not been firmly established. Postulated mechanisms include prejunctional suppression o…

0301 basic medicineAgonistmedicine.medical_specialtyAdrenergic receptormedicine.drug_classUrinary BladderAdrenergic beta-3 Receptor Agonistsurologic and male genital diseasesThemed Section: Review Articles03 medical and health sciences0302 clinical medicineTherapeutic indexDesensitization (telecommunications)Internal medicineMedicineAnimalsHumansPharmacologyUrinary bladderRelaxation (psychology)business.industry030104 developmental biologymedicine.anatomical_structureEndocrinologyMechanism of actionReceptors Adrenergic beta-3medicine.symptombusinessMirabegron030217 neurology & neurosurgerymedicine.drug
researchProduct

Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles

2020

Despite improvements in donor screening and increasing efforts to avoid contamination and the spread of pathogens in clinical platelet concentrates (PCs), the risks of transfusion-transmitted infections remain important. Relying on an ultraviolet photo activation system, pathogen reduction technologies (PRTs), such as Intercept and Mirasol, utilize amotosalen, and riboflavin (vitamin B2), respectively, to mediate inactivation of pathogen nucleic acids. Although they are expected to increase the safety and prolong the shelf life of clinical PCs, these PRTs might affect the quality and function of platelets, as recently reported. Upon activation, platelets release microparticles (MPs), which …

0301 basic medicineAmotosalenmedicine.medical_specialtySmall RNAlcsh:Diseases of the circulatory (Cardiovascular) systemmirasolCardiovascular Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineclinical platelet concentrateInternal medicinemicroRNAmedicinePlateletHematologiPathogenOriginal ResearchRegulation of gene expressionHematologymicroRNApathogen reductionChemistryclinical platelet concentrate; pathogen reduction; mirasol; intercept; extracellular vesicles; small RNA-sequencing; microRNAHematology3. Good healthCell biologysmall RNA-sequencing030104 developmental biologylcsh:RC666-701extracellular vesiclesCardiology and Cardiovascular MedicineFunction (biology)interceptFrontiers in Cardiovascular Medicine
researchProduct

Review of imaging network activities in developing rodent cerebral cortex in vivo

2016

The combination of voltage-sensitive dye imaging (VSDI) with multielectrode array (MEA) recordings in the rodent cerebral cortex in vivo allows the simultaneous analysis of large-scale network interactions and electrophysiological single-unit recordings. Using this approach, distinct patterns of spontaneous and sensory-evoked activity can be recorded in the primary somatosensory (S1) and motor cortex (M1) of newborn rats. Already at the day of birth, gamma oscillations and spindle bursts in the barrel cortex synchronize the activity of a local columnar ensemble, thereby generating an early topographic representation of the sensory periphery. During the first postnatal week, both cortical ac…

0301 basic medicineNeocortexRadiological and Ultrasound TechnologyNeuroscience (miscellaneous)Sensory systemMultielectrode arrayBiologyBarrel cortexSomatosensory system03 medical and health sciencesElectrophysiology030104 developmental biology0302 clinical medicinemedicine.anatomical_structureCerebral cortexmedicineRadiology Nuclear Medicine and imagingPioneers in Neurophotonics: Special Section Honoring Professor Amiram GrinvaldNeuroscience030217 neurology & neurosurgeryMotor cortexNeurophotonics
researchProduct

The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

2017

Background and Purpose Mirabegron has been classified as a β3-adrenoceptor agonist approved for overactive bladder syndrome. We investigated possible cardiac effects of mirabegron in the absence or presence of β-adrenoceptor subtype antagonists. In view of its phenylethanolamine structure, we investigated whether mirabegron has indirect sympathomimetic activity by using neuronal uptake blockers. Experimental Approach Right atrial trabeculae, from non-failing hearts, were paced and contractile force measured at 37°C. Single concentrations of mirabegron were added in the absence or presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), β3 (L-748,337), β1 (CGP 20712A),…

0301 basic medicinePharmacologyAgonistmedicine.medical_specialtyIBMXContraction (grammar)PhenoxybenzamineChemistrymedicine.drug_classAdrenergicPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biologyEndocrinologyInternal medicineDesipraminemedicinePhosphodiesterase inhibitorMirabegronmedicine.drugBritish Journal of Pharmacology
researchProduct

How β3 -adrenoceptor-selective is mirabegron?

2016

0301 basic medicinePharmacologybusiness.industryAdrenergic beta-3 Receptor AgonistsPharmacology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicineβ3 adrenoceptorMirabegronbusiness030217 neurology & neurosurgerymedicine.drugBritish Journal of Pharmacology
researchProduct

A Process × Domain Assessment of Narcissism: The Domain-Specific Narcissistic Admiration and Rivalry Questionnaire

2022

Research on grandiose narcissism distinguishes between self-promotional processes (i.e., narcissistic admiration) and other-derogative processes (i.e., narcissistic rivalry; Back et al., 2013). Moreover, research has begun to assess and investigate narcissistic manifestations in different domains (e.g., communal narcissism). To integrate these two lines of research, we developed the Domain-Specific Narcissistic Admiration and Rivalry Questionnaire (D-NARQ), a 72-item narcissism questionnaire that contains a self-promotional process scale (narcissistic admiration) and an other-derogatory process scale (narcissistic rivalry) for four domains: intellectual ability, social dominance, communal …

050103 clinical psychologySelf-AssessmentPsychoanalysiscommunionAdmirationPsychometricsphysical attractiveness05 social sciencesPhysical attractiveness050109 social psychologyintelligenceDomain (software engineering)social statusClinical PsychologySurveys and QuestionnairesNarcissismmedicineHumans0501 psychology and cognitive sciencesnarcissismmedicine.symptomPsychologyRivalryApplied Psychology
researchProduct

Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales

2014

“Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales” es la primera parte de un trabajo de documentación para un capítulo de “La democracia en la Comunidad Valenciana. Partidos, elites políticas, elecciones y programas políticos”. “Mujer, poder político y democracia paritaria”. Se recoge el papel de la mujer en la vida política de la Comunidad Valenciana en la democracia actual, desde 1977. Es documentación sin elaborar, pero que aporta datos de la presencia de la mujer en las instituciones, partidos y sindicatos. Cuando este completa será una parte de la investigación referida, y de la que ya hay dos publicacion…

:CIENCIA POLÍTICA [UNESCO]UNESCO::HISTORIAUNESCO::CIENCIA POLÍTICA:HISTORIA [UNESCO]Dolores Ibarruri Pasionaria. Josefina López Sanmartín PCE. Ciprià Císcar Casabán. Pilar Brabo Castells. Palmira Pla Pechoviento. Adela Pla Pastor. democracia paritaria. Asunción Cruañes Molina. Carmen Alborch Bataller. Maria A. Armengol Criado. Clementina Rodenas Villena. Rita Barberá Nolla. Irma Simón Calvo. Teresa Sempere Jaén. Ofelia Soler Nomdedeu. María C. Díaz Villanueva. María Carmen Pardo Raga. Eva María Amador Guillén. Presentación Urán González. María Isabel Díez de la Lastra Barbadillo. Elena Irene Martín Crevillén. María Enriqueta Seller Roca de Togores. María Carmen Pardo Raga. Eva María Amador Guillén. María J. Mora Devis. Olga Mulet Torres. Margarita Pin Arboledas. Juana Serna Masiá. Leire Pajín Iraola. Rosa M. Peris Cervera. Amparo Ferrando. Carmen Arjona. María I. España Moya. Federica Montseny Mañé. Matilde Fernández Sanz. Rosa Conde Gutiérrez del Álamo. María de los Ángeles Amador Millán. Cristina Alberdi Alonso. Margarita Mariscal de Gante Mirón. Esperanza Aguirre Gil de Biedma. Loyola de Palacio del Valle-Lersundi. Isabel Tocino Biscarolasaga. Pilar del Castillo Vera. Celia Villalobos Talero. Anna María Birulés Beltrán Ana Pastor. Ana de Palacio del Valle-Lersundi. Elvira Rodríguez Herrero. Julia García-Valdecasas. Ana Mª Castellanos Vilar. Elena Mª Martín Yánez. Paloma Gómez Osorio. Concepción Pérez Morales. Francisca Benabent Fuentes. Carmen Monzó Juan. Rosa Mª Morte Julián. Gloria Marcos Martí. Lourdes Alonso Belza. Pilar Pedraza. María García-Lliberos Sánchez-Robles. Blanca Blanquer. Dolors Giner Duran. Teresa Fluvía Rodríguez. Trinidad Simó. Emilia Noguera. Hortensia Moriones Almaraz. Carolina García Mahiques. Hortensia Moriones Almaraz. Juana Serna Maciá. Lourdes Alonso Belza. Inmaculada Rodríguez-Piñero Fdez. Carmen Macián Armengod. Carmen Moya García. María José López Rodenas. María Juan Millet. Alicia de Miguel García. Ana Encabo Balbín. Ana Michavila Nuñez. Isabel Villalonga Campos. Carmen Dolz Adell. Eva Maria Amador Guillen. Alida C. Mas Taberner. Dora Ibars Sancho. Amparo Koninckx Frasquet. Blanca Martínez de Vallejo Fuster. Consuelo Císcar Casabán. Auxiliadora Hernández Miñana. Silvia Caballer Almela. Gemma Amor Pérez. Emma Iranzo Martín. Cristina Serrano Mateo. Cristina Santamarina Ciurana
researchProduct